Michael Goldberg, Surge Therapeutics CEO

Backed by Bob Langer, for­mer Har­vard prof sets out to test a new way to de­liv­er I/O drugs — dur­ing surgery

Every year, mil­lions of can­cer pa­tients un­der­go surgery to get their tu­mors re­moved. But while re­sec­tion can stave off can­cer for some time, as many …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.